Cambodia

Located in the Greater Mekong Subregion (GMS), Cambodia was a signatory of the APLMA roadmap in 2015.

‍

While cases in Cambodia have steadily declined, malaria is increasingly focalized in hard-to-reach areas, especially in forest-fringe and deep-forest areas in the Northeastern and Southwestern regions. Since late 2020, the country has been implementing the Last Mile Project, a package of interventions, including targeted drug administration (TDA) for the highest risk group, intermittent preventive therapy for forest-goers (IPTf), and weekly active fever screening (AFS) to accelerate elimination of P. falciparum. This has been further expanded to P. vivax indigenous cases since 2024. Having completed a Sustainability & Transition Readiness Assessment in 2021, Cambodia is also increasing its efforts towards sustainability planning.  

‍

Cambodia is part of the Regional Artemisinin-resistance Initiative (RAI), a special multi-country award from the Global Fund which aims to accelerate malaria elimination in the GMS, including drug-resistant P. falciparum malaria. Like other countries in the GMS, Cambodia also faces the challenges of an increasing proportion of P. vivax malaria.

‍

Currently among the countries making up 1% of the Asia Pacific’s malaria burden, Cambodia aims to eliminate all species of human malaria by 2025.